Closed · W81XWH-10-NFRP-CTA · CFDA 12.420 · Discretionary

DoD Neurofibromatosis Clinical Trial Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
May 20, 2010
Close date
2
Expected awards

The verdict

DoD Neurofibromatosis Clinical Trial Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
2
expected awards
12.420
CFDA program

Archived opportunity record

DoD Neurofibromatosis Clinical Trial Award is closed (last close May 20, 2010). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed May 20, 2010

Posted Feb 23 Closes May 20

Est. Total Funding

$2,700,000

Expected Awards

2

Instrument

Grant

Description

The NFRP Clinical Trial Award (CTA) mechanism was first offered in FY99. Since then, 23 CTA applications have been received, and 6 have been recommended for funding. DOD FY10 Neurofibromatosis Clinical Trial Award 3 The NFRP CTA supports research with the potential to have a major impact on the treatment or management of neurofibromatosis and/or Schwannomatosis. Funding from this award mechanism must support a clinical trial. In general, a clinical trial is defined as a prospective accrual of patients for a study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects. The proposed clinical trial is expected to begin no later than 12 months after the award date. Preliminary data, unpublished results from the laboratory of the Principal Investigator (PI) or collaborators named on this application, that is relevant to the proposed research project is required. Proposals should also be based on a sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature. Funding from this award mechanism cannot be used for preclinical research studies. PIs seeking funding for a preclinical research project should consider one of the other award mechanisms/funding opportunities being offered. Each application should contain only one clinical trial with a distinct study design. Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications should be submitted or approved prior to application submission. If the study is in support of an application to the U.S. Food and Drug Administration (FDA), Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications should be submitted prior to the grant application submission. The Government reserves the right to withdraw funding if an active exemption from marketing approval for the IND or IDE has not been acquired within 6 months of the award date. If an IND or IDE is required to conduct the proposed research, but is not received within 6 months of the award date, the Government reserves the right to revoke funding. For descriptions of each type of clinical trial, please refer to http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/default.htm and http://www.clinicaltrials.gov. Refer to the General Application Instructions, Appendix 5, for helpful information about distinguishing clinical trials and research utilizing human anatomical substances. Again, the proposed clinical trial is expected to begin no later than 12 months after the award date. The following are important aspects of submission for the CTA: • Include a prospective accrual of subjects for a study where an intervention (e.g., drug, device, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. • Demonstrate availability of, and access to, a suitable volunteer population that will support a meaningful outcome for the study. Discuss how accrual goals will be achieved and how standards of care may impact the study population. • Describe clearly defined and appropriate endpoints for the proposed clinical trial. • Clearly articulate the statistical analysis plan. Include a power analysis reflecting sample size projections that will clearly answer the objectives of the study. • Discuss the potential impact of the study results for patients with neurofibromatosis or Schwannomatosis. DOD FY10 Neurofibromatosis Clinical Trial Award 4 • Include a study coordinator(s) who will guide the clinical protocol through Institutional Review Board (IRB), Human Subjects Research Review Board, and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. • Demonstrate institutional support.

Catch-all / unrestricted eligibility mark · W81XWH-10-NFRP-CTA

Grants.gov marks DoD Neurofibromatosis Clinical Trial Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil eReceipt HELP: 301-682-5507; help@cdmrp.org

What to do next

DoD Neurofibromatosis Clinical Trial Award is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants